Speaker illustration

Doctor Heike Schwende

Novartis Pharma AG, Basel (Switzerland)

Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Heart failure pharmacotherapy - Sacubitril/valsartan

Thumbnail

This platform is supported by

logo Novo Nordisk